|Bid||0.00 x 800|
|Ask||0.00 x 800|
|Day's Range||7.07 - 7.39|
|52 Week Range||6.20 - 11.44|
|Beta (3Y Monthly)||2.55|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Nassim Usman became the CEO of Catalyst Biosciences, Inc. (NASDAQ:CBIO) in 2015. First, this article will compare CEO...
This most-searched list is a feature included in Benzinga Pro's Newsfeed tool. It highlights stocks frequently searched by Benzinga Pro users on the platform. Sangamo Therapeutics, Inc . (NASDAQ: SGMO ...
If you are building a properly diversified stock portfolio, the chances are some of your picks will perform badly. But...
Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! If you want to know who really controls Catalyst Biosciences, Inc. (NASDAQ:CBIO), then you'll have to look at the makeup of i...
Catalyst Biosciences Inc is a clinical-stage biopharmaceutical company. The Company is engaged in creating and developing novel medicines to address serious medical conditions. Catalyst Biosciences Inc had annual average EBITDA growth of 33.50% over the past five years.For the latest fiscal year the company reported a revenue of $0.01 million, a decrease of 99.4% from the previous year.
Catalyst Biosciences, Inc. (NASDAQ:CBIO), which has zero-debt on its balance sheet, can maximize capital returns by increasing debt due to its lower cost of capital. However, the trade-off is CBIO Read More...
Zacks.com featured expert Kevin Matras highlights: Net Lease, K12, Brookline Bancorp, Catalyst Biosciences and Knoll
Nassim Usman became the CEO of Catalyst Biosciences Inc (NASDAQ:CBIO) in 2015. First, this article will compare CEO compensation with compensation at similar sized companies. Then we’ll look at a Read More...
Catalyst Biosciences Inc (NASDAQ:CBIO), a US$112.1m small-cap, operates in the healthcare industry, which has experienced tailwinds from issues such as higher demand driven by an aging population and the increasingRead More...